All In Biotech

Drug Trial Radar · NCT07090655

A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous and Intravenous Injections of Budoprutug (TNT119) in Normal Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Aug 11, 2025

Primary completion

Apr 7, 2026

Study completion Apr 7, 2026

Sponsor

Lead sponsor
Climb Bio, Inc.Industry
Sponsor type
Industry
First posted
Jul 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective is to assess the safety and tolerability of subcutaneous and intravenous injection forms of budoprutug in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

  • BudoprutugDrug

    Subcutaneous or IV administration

  • PlaceboDrug

    Placebo comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of Single Ascending Doses of budoprutug in Healthy ParticipantsTime frame: Day 57
  2. Incidence of infusion-related reactions (IRRs) for IV administrationTime frame: Day 57
  3. Incidence of injection site reactions (ISRs) for SC administrationTime frame: Day 57

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Brisbane

    Brisbane, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.